et the question remains on the best way to predict these complications. It is relevant to consider prophylactic measures for avoiding hypercoagulability. Progressive diffuse abdominal discomfort with no important alterations on coagulation profile or other danger aspects really should raise the awareness for mesenteric thrombosis. Really, couple of instances of intestinal thrombosis exist inside the literature considering our patient certainly one of the first instances of subacute mesenteric venous thrombosis in a non-severe COVID-19 patient. Far more case reports and descriptive data are required in the literature to boost the index of suspicion for these kinds of complications.research concluding that there is no difference in collateral formation, recanalization and mortality, regardless of whether anticoagulation had been prescribed or not. These findings emphasize the predominant function of inflammation, escalating uncertainty of risk/benefit ratio of anticoagulation. When portal and superior mesenteric veins are impacted, anticoagulation seems a reasonable attitude, taking into consideration the threat of hepatic decompensation and bowel ischemia. A lot more studies are necessary to consolidate this proof and to establish well-defined suggestions in other circumstances (e.g., isolated thrombosis of splenic vein, as in this case).V T E D I AG N O S I S PB1175|Detection of Correct Ventricular Dysfunction in Acute Pulmonary Embolism by CT Scan: A Systematic Evaluation and Metaanalysis N. Chornenki1; K. Poorzargar2; M. Shanjer2; L. Dopamine Receptor Agonist medchemexpress Mbuagbaw2;PB1174|Does Anticoagulation Impact Outcome of Splenic Vein Thrombosis in Acute Pancreatitis L. Vieira; S. Lopes; R. Pombal; R. Neto; A. Magalh s; M. Figueiredo Immunohemotherapy Service, Vila Nova de Gaia/Espinho Hospital Centre, Vila Nova de Gaia, Portugal Background: Splanchnic venous thrombosis (SVT) is a wellestablished complication of acute pancreatitis (AP) and might impact splenic, portal and superior mesenteric veins, either isolated or in mixture. Its pathogenesis is closely associated to inflammation, leading to cellular infiltration, formation of pancreatic/peripancreatic collections that contribute to venous stasis and systemic activation of haemostasis. Aims: Description of a case of SVT AP-associated. Strategies: Collection of clinical data in SCl ico application. Outcomes: A 47-year-old female patient, with antecedents of previous AP secondary to hypertriglyceridemia, was admitted to emergency division with pain in upper quadrants of abdomen, radiating towards the back, with nausea and vomiting, more than the previous couple of hours. Through clinical, analytical and imaging evaluation, the diagnosis of AP secondary to hypertriglyceridemia was established. The patient was hospitalized and, four days later, as a result of clinical worsening, a computed tomography (CT) was performed, revealing splenic vein thrombosis and pancreatic necrosis. Enoxaparin in therapeutic dose was initiated. The patient remained hospitalized for 18 days and enoxaparin was replaced by rivaroxaban 20mg once everyday at discharge. 3 months later, CT showed persistence of thrombosis, with perigastric/perisplenic collateral circulation. Contemplating this in depth collateral circulation, complete recanalization was no longer expected. Anticoagulation was maintained to get a total period of six months. Conclusions: Management of thrombosis in AP remains challenging. There is no consensus on anticoagulation within this COX-1 Inhibitor MedChemExpress setting, with someM. Crowther2; A. Delluc3; D. SiegalQueens University, Kingston, Canada; 2McMaster University,Hamilton, Cana
